ObjectiveTo investigate the effect of sequential use of bifid triple viable in the eradication treatment of Helicobacter pylori (HP). MethodsA total of 183 HP positive chronic gastritis patients with gastric mucosa atrophy or erosion treated between October 2012 and October 2014 were randomly divided into three groups with 61 in each. The triple group received standard one-week triple therapy. The quadruple group received standard two-week quadruple therapy. The bifid triple viable group was given one week of standard quadruple therapy and one week of sequential bifid triple viable. One month after withdrawal of the medicine, HP eradication rate, clinical efficacy and adverse reactions were compared among the three groups. ResultsThe HP eradication rate in the triple group was 72.13%, significantly lower than that in the quadruple group (93.44%) and in the bifid triple viable group (90.16%) (P < 0.05). The HP eradication rate in the bifid triple viable group was slightly lower than that in the quadruple group (P > 0.05). The total effective rate in the quadruple group and bifid triple viable group was respectively 95.08% and 91.80%, with no significant difference between the two groups (P > 0.05), but they both were significantly higher than that in the bifid triple viable group (P < 0.05). Eleven cases of adverse reactions happened during the process of eradication treatment of HP. The adverse reactions were not serious, and could be solved with symptomatic treatments. The adverse reaction rate in the quadruple group was significantly higher than that in the bifid triple viable group (P < 0.05). ConclusionSequential use of bifid triple viable capsule can improve the rate of HP eradication, relieve the clinical symptoms effectively, reduce adverse reactions, and reduce the medical cost.